论文部分内容阅读
目的观察地塞米松缓释微粒植入前房内对控制糖尿病性年龄相关性白内障人工晶状体植入术后炎症的作用。方法对60例糖尿病性年龄相关性白内障患者行小切口非超声乳化人工晶状体植入术,其中30例植入地塞米松缓释微粒,另30例为对照组。观察术后1、3、7d房水混浊和纤维蛋白渗出及膜形成情况。结果植入地塞米松缓释微粒组明显轻于对照组,两组差异具有显著性(P<0.05)。结论地塞米松缓释微粒植入前房控制术后炎症安全、有效、可靠。
Objective To observe the effect of dexamethasone sustained-release particles implanted in the anterior chamber on the inflammation of diabetic age-related cataract intraocular lens implantation. Methods Sixty cases of diabetic age-related cataract patients underwent small incision non-phacoemulsification intraocular lens implantation, of which 30 cases were implanted with dexamethasone sustained-release particles and the other 30 cases were control group. The aqueous humor and fibrin exudation and membrane formation at 1, 3 and 7 days after operation were observed. Results Dexamethasone sustained-release particles were significantly lighter than the control group, the difference between the two groups was significant (P <0.05). Conclusion Dexamethasone sustained-release particles implanted in the anterior chamber after the control of inflammation is safe, effective and reliable.